Drugs / NVP-2203-R2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05725252 | May → Jun 2023 | — | NVP Healthcare | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05856487 Comparator | Jun 2023 → May 2024 | cardiovascular disorder | NVP Healthcare | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NVP-2203-R2 | “NVP-2203(Combination of NVP-2203-R1 and NVP-2203-R2)” NCT05725252 ↗ |
| Route | Oral | “oral administration of investigational product once daily” NCT05725252 ↗ |